View in EDS HTML Full Text PDF Full Text

Differential responses to the combination of navitoclax and venetoclax with doxorubicin in murine models of triple negative breast cancer.

Saved in:
Bibliographic Details
Title: Differential responses to the combination of navitoclax and venetoclax with doxorubicin in murine models of triple negative breast cancer.
Authors: As Sobeai HM; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia., Alanazi AM; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.; Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Centre, Madinah, Saudi Arabia., Alotaibi F; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.; Inpatient Pharmacy Department, King Fahad Medical City, Riyadh, Saudi Arabia., Alhoshani A; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia., Alhazzani K; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia., Almutairi MM; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia., Almudimeegh S; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia., Al-Ramadi BK; Department of Medical Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates., Chakraborty E; Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States.; Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA, United States., Saleh T; Department of Pharmacology & Therapeutics, College of Medicine and Health Sciences, Arabian Gulf University, Manama, Bahrain.; Department of Pharmacology and Public Health, Faculty of Medicine, The Hashemite University, Zarqa, Jordan., Gewirtz DA; Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States.; Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA, United States., Harada H; Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA, United States.; School of Dentistry, Philips Institute for Oral Health Research, Virginia Commonwealth University, Richmond, VA, United States., Alotaibi MR; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Source: Frontiers in cell and developmental biology [Front Cell Dev Biol] 2026 Feb 05; Vol. 14, pp. 1661424. Date of Electronic Publication: 2026 Feb 05 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101630250 Publication Model: eCollection Cited Medium: Print ISSN: 2296-634X (Print) Linking ISSN: 2296634X NLM ISO Abbreviation: Front Cell Dev Biol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41727313
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Differential responses to the combination of navitoclax and venetoclax with doxorubicin in murine models of triple negative breast cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22As+Sobeai+HM%22">As Sobeai HM</searchLink>; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.<br /><searchLink fieldCode="AU" term="%22Alanazi+AM%22">Alanazi AM</searchLink>; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.; Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Centre, Madinah, Saudi Arabia.<br /><searchLink fieldCode="AU" term="%22Alotaibi+F%22">Alotaibi F</searchLink>; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.; Inpatient Pharmacy Department, King Fahad Medical City, Riyadh, Saudi Arabia.<br /><searchLink fieldCode="AU" term="%22Alhoshani+A%22">Alhoshani A</searchLink>; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.<br /><searchLink fieldCode="AU" term="%22Alhazzani+K%22">Alhazzani K</searchLink>; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.<br /><searchLink fieldCode="AU" term="%22Almutairi+MM%22">Almutairi MM</searchLink>; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.<br /><searchLink fieldCode="AU" term="%22Almudimeegh+S%22">Almudimeegh S</searchLink>; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.<br /><searchLink fieldCode="AU" term="%22Al-Ramadi+BK%22">Al-Ramadi BK</searchLink>; Department of Medical Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.<br /><searchLink fieldCode="AU" term="%22Chakraborty+E%22">Chakraborty E</searchLink>; Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States.; Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA, United States.<br /><searchLink fieldCode="AU" term="%22Saleh+T%22">Saleh T</searchLink>; Department of Pharmacology & Therapeutics, College of Medicine and Health Sciences, Arabian Gulf University, Manama, Bahrain.; Department of Pharmacology and Public Health, Faculty of Medicine, The Hashemite University, Zarqa, Jordan.<br /><searchLink fieldCode="AU" term="%22Gewirtz+DA%22">Gewirtz DA</searchLink>; Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States.; Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA, United States.<br /><searchLink fieldCode="AU" term="%22Harada+H%22">Harada H</searchLink>; Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA, United States.; School of Dentistry, Philips Institute for Oral Health Research, Virginia Commonwealth University, Richmond, VA, United States.<br /><searchLink fieldCode="AU" term="%22Alotaibi+MR%22">Alotaibi MR</searchLink>; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101630250%22">Frontiers in cell and developmental biology</searchLink> [Front Cell Dev Biol] 2026 Feb 05; Vol. 14, pp. 1661424. <i>Date of Electronic Publication: </i>2026 Feb 05 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Media+S%2EA%22">Frontiers Media S.A </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101630250 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2296-634X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222296634X%22">2296634X </searchLink><i>NLM ISO Abbreviation: </i>Front Cell Dev Biol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41727313
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fcell.2026.1661424
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1661424
    Titles:
      – TitleFull: Differential responses to the combination of navitoclax and venetoclax with doxorubicin in murine models of triple negative breast cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: As Sobeai HM
      – PersonEntity:
          Name:
            NameFull: Alanazi AM
      – PersonEntity:
          Name:
            NameFull: Alotaibi F
      – PersonEntity:
          Name:
            NameFull: Alhoshani A
      – PersonEntity:
          Name:
            NameFull: Alhazzani K
      – PersonEntity:
          Name:
            NameFull: Almutairi MM
      – PersonEntity:
          Name:
            NameFull: Almudimeegh S
      – PersonEntity:
          Name:
            NameFull: Al-Ramadi BK
      – PersonEntity:
          Name:
            NameFull: Chakraborty E
      – PersonEntity:
          Name:
            NameFull: Saleh T
      – PersonEntity:
          Name:
            NameFull: Gewirtz DA
      – PersonEntity:
          Name:
            NameFull: Harada H
      – PersonEntity:
          Name:
            NameFull: Alotaibi MR
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 05
              M: 02
              Text: 2026 Feb 05
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 2296-634X
          Numbering:
            – Type: volume
              Value: 14
          Titles:
            – TitleFull: Frontiers in cell and developmental biology
              Type: main
ResultId 1